- Home
- BGLC vs OMH Comparison
BGLC vs OMH Comparison
Compare BGLC & OMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- OMH
- Stock Information
- Founded
- BGLC 2017
- OMH 2015
- Country
- BGLC Malaysia
- OMH Singapore
- Employees
- BGLC N/A
- OMH N/A
- Industry
- BGLC Medical Specialities
- OMH Real Estate
- Sector
- BGLC Health Care
- OMH Finance
- Exchange
- BGLC Nasdaq
- OMH Nasdaq
- Market Cap
- BGLC 5.8M
- OMH N/A
- IPO Year
- BGLC N/A
- OMH 2023
- Fundamental
- Price
- BGLC $0.25
- OMH $2.23
- Analyst Decision
- BGLC
- OMH Strong Buy
- Analyst Count
- BGLC 0
- OMH 1
- Target Price
- BGLC N/A
- OMH $15.00
- AVG Volume (30 Days)
- BGLC 1.5M
- OMH 17.0K
- Earning Date
- BGLC 05-14-2025
- OMH 01-01-0001
- Dividend Yield
- BGLC N/A
- OMH N/A
- EPS Growth
- BGLC N/A
- OMH N/A
- EPS
- BGLC N/A
- OMH N/A
- Revenue
- BGLC $9,259,858.00
- OMH $5,390,607.00
- Revenue This Year
- BGLC N/A
- OMH $111.47
- Revenue Next Year
- BGLC N/A
- OMH $32.08
- P/E Ratio
- BGLC N/A
- OMH N/A
- Revenue Growth
- BGLC N/A
- OMH 25.77
- 52 Week Low
- BGLC $0.21
- OMH $0.25
- 52 Week High
- BGLC $1.00
- OMH $2.70
- Technical
- Relative Strength Index (RSI)
- BGLC 35.57
- OMH 63.38
- Support Level
- BGLC $0.23
- OMH $2.12
- Resistance Level
- BGLC $0.29
- OMH $2.31
- Average True Range (ATR)
- BGLC 0.02
- OMH 0.23
- MACD
- BGLC -0.01
- OMH -0.07
- Stochastic Oscillator
- BGLC 20.22
- OMH 25.34
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.